New money-saver technology for heart patients needing PCI

A study presented at the American College of Cardiology annual meeting by Duke cardiologists shows that an invasive instantaneous wave-free ratio (iFR) method carries...

Autism could be predicted from blood or urine tests soon

In a new study, a team of researchers from the University of Warwick and the University of Bologna have found blood and urine chemical...

New target antigen could make CAR-T possible for glioblastomas

Surgery, radiation and chemotherapy just don’t cut it against glioblastoma, a type of aggressive brain tumor with a dismal five-year survival rate. To tackle the...

New study identifies possible target for treatment of dangerous allergic reactions

Research conducted at Cincinnati Children's Hospital Medical Center and published in the Journal of Allergy and Clinical Immunology found that several proteins can interact in blood...

FDA Approves First Home Test for Breast Cancer GenesN

The first consumer test for three BRCA gene mutations associated with breast, ovarian and prostate cancer risk has been approved by the U.S. Food...

Myriad Genetics fights against colorectal cancer

Myriad Genetics Inc., a leader in molecular diagnostics and personalized medicine, continues to demonstrate an unmatched commitment to hereditary cancer risk assessment and genetic...

Growth of fusion imaging in nuclear medicine

A latest trend gaining momentum in the market is developing hybrid imaging systems, propelled by the recent introduction of PET/MRI hybrid systems. From the evolution...

Specialized nanotechnology could reduce pain in oral surgery

Researchers reported a pre-clinical study in ACS Nano showing that they could potentially reduce pain and recovery time with the aid of specialized nanotechnology. Previous...

FDA approves first blood test to aid in diagnosis of concussions

The FDA has approved a blood test for use in the detection of concussion for the first time. Banyan Biomarkers picked up the approval after showing...

Eurofins licenses SenzaGen’s genome-based chemical allergy test

Chemical allergy test developer SenzaGen has signed its first global licensing agreement, allowing incorporation of its GARD test in Eurofins Munich’s human safety testing...